Dinaciclib treatment demonstrated antitumor activity in 2 of 7 patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer ( 1 confirmed and 1 unconfirmed partial response ) , as well as acceptable safety and tolerability .